Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 30

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 30
---
iciency and Noonan Syndrome without sufficient response to human growth hormone, in addition to a Phase 2 study for children with idiopathic short stature.

For TYRA-200 in ICC, there are two pan-FGFR inhibitors available in the United States that are indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement: Incyte Corporation’s Pemazyre and Taiho Oncology’s Lytgobi. Additional inhibitors in development include Elevar’s Lirafugratinib, TransThera’s tinengotinib and Cogent’s CGT-4859.

For TYRA-430 in HCC, several multi-kinase inhibitors have been approved for the treatment of HCC, but there are currently no approved FGFR4-specific inhibitors approved.  In the late line setting, approved, non-targeted treatment options include Bayer’s Stivarga, Exelixis’ Cabometyx, Eli Lilly’s Cyramza, Merck’s Keytruda and BMS’ Opdivo combined with Yervoy. There are a number of FGFR4 clinical stage programs, with most of the development focused in China, including CStone Pharmaceuticals and Blueprint Medicine’s BLU-554 (fisogatinib), Everest Medicine’s FGF401 and Abbisko Therapeutics’ ABSK-011.

Intellectual Property

We strive to protect the intellectual property and proprietary technology that we consider important to our business through a variety of methods, including seeking and maintaining patents intended to cover our product 

16

candidates and compositions, their methods of use and processes for their manufacture, and any other inventions that are important to our business. We rely on know-how and continuing technological innovation to develop and maintain our proprietary position. We also rely on trade secrets and know-how that may be important to the development of our business. We seek to obtain domestic and international patent protection and endeavor to promptly file patent applications for new commercially valuable inventions to expand our intellectual property portfolio.

We are building a patent portfolio and have substantial confidential know-how relating to our product candidates and SNÅP platform. As of March 15, 2025, our intellectual property portfolio consists of one granted U.S. patent, 14 pending U.S. provisional applications, 10 pending U.S. nonprovisional applications, 90 pending foreign patent applications, one granted foreign patent and 10 patent applications pursuant to the Patent Cooperation Treaty